User login
Key clinical point: Prostrate-specific antigen (PSA) testing increased after the 2017 United States Preventive Services Task Force (USPSTF) draft statement for prostate cancer screening.
Major finding: A relative increase of 12.5% was seen in the PSA testing rate during 2016-2019. A relative increase of 10.1%, 12.1%, and 16.2% was seen in men aged 40-54 years, 55-69 years, and 70-89 years. A significantly increasing trend of PSA testing was seen after the release of USPSTF draft in April 2017 (0.30 tests per 100 person-years for each bimonthly period; P < .001).
Study details: This retrospective cohort study of 8,087,565 men aged 40 to 89 years who underwent prostate cancer screening between 2013 and 2019.
Disclosures: This work was funded by National Institutes of Health/National Cancer Institute. The authors received grants, honoraria, and consulting/personal/speaker fees from various sources.
Source: Leapman MS et al. JAMA Oncol. 2021 Nov 11. doi: 10.1001/jamaoncol.2021.5143.
Key clinical point: Prostrate-specific antigen (PSA) testing increased after the 2017 United States Preventive Services Task Force (USPSTF) draft statement for prostate cancer screening.
Major finding: A relative increase of 12.5% was seen in the PSA testing rate during 2016-2019. A relative increase of 10.1%, 12.1%, and 16.2% was seen in men aged 40-54 years, 55-69 years, and 70-89 years. A significantly increasing trend of PSA testing was seen after the release of USPSTF draft in April 2017 (0.30 tests per 100 person-years for each bimonthly period; P < .001).
Study details: This retrospective cohort study of 8,087,565 men aged 40 to 89 years who underwent prostate cancer screening between 2013 and 2019.
Disclosures: This work was funded by National Institutes of Health/National Cancer Institute. The authors received grants, honoraria, and consulting/personal/speaker fees from various sources.
Source: Leapman MS et al. JAMA Oncol. 2021 Nov 11. doi: 10.1001/jamaoncol.2021.5143.
Key clinical point: Prostrate-specific antigen (PSA) testing increased after the 2017 United States Preventive Services Task Force (USPSTF) draft statement for prostate cancer screening.
Major finding: A relative increase of 12.5% was seen in the PSA testing rate during 2016-2019. A relative increase of 10.1%, 12.1%, and 16.2% was seen in men aged 40-54 years, 55-69 years, and 70-89 years. A significantly increasing trend of PSA testing was seen after the release of USPSTF draft in April 2017 (0.30 tests per 100 person-years for each bimonthly period; P < .001).
Study details: This retrospective cohort study of 8,087,565 men aged 40 to 89 years who underwent prostate cancer screening between 2013 and 2019.
Disclosures: This work was funded by National Institutes of Health/National Cancer Institute. The authors received grants, honoraria, and consulting/personal/speaker fees from various sources.
Source: Leapman MS et al. JAMA Oncol. 2021 Nov 11. doi: 10.1001/jamaoncol.2021.5143.